SURVYR

CYTK

Cytokinetics, Incorporated
$61.52
+$0.79 (1.30%)Oct 27 close
Health CareS&P 400 CompareTechnicals
1M3M6M1Y2Y
-7%+6%+20%+33%+47%Oct 2025Oct 2026Apr 202652w high $88.3152w low $57.83
CYTKSPY
Wall St. Highest PT $146.00 (+137.3%) Wall St. Avg PT $109.20 (+77.5%)
$59$86$113$140$168POC $62Hi $146Avg $109
Underwater Drawdown %Max DD -30.4%Current -29.5%
0.0%-30.4%
Relative Strength vs SPY-11.3% vs SPYUnderperforming
+41%0%-41%
1W
−$2.43 (3.80%)
1M
−$3.14 (4.86%)
3M
−$17.93 (22.57%)
6M
+$0.83 (1.37%)
YTD
−$2.02 (3.18%)
1Y
+$1.34 (2.23%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
23 analysts · mean score 1.48
1 = Strong Buy · 5 = Sell
Strong Buy730%
Buy1461%
Hold29%
Underperform00%
Sell00%
Wall Street consensus
Analyst price targets
Current price$61.52
Average target$109.20
+$47.68 (+77.5%) upsideaverage target vs current price
CurrentAverageMedian
Low$81.00
Median$106.00
High$146.00
12-month Wall Street target range
Recent analyst rating changes · 30
Reiterated
2026-10-19 · HC Wainwright & Co. reiterated Buy on CYTK
Initiated
2026-10-16 · William Blair started covering CYTK at Outperform
Reiterated
2026-10-08 · RBC Capital reiterated Outperform on CYTK
Reiterated
2026-08-31 · HC Wainwright & Co. reiterated Buy on CYTK
Reiterated
2026-08-13 · Barclays reiterated Overweight on CYTK
Reiterated
2026-08-13 · JP Morgan reiterated Overweight on CYTK
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$8.5B
P/E (next 12 months, estimated)-13.9
52-week range$57.83 – $88.31
Revenue growth (latest quarter vs a year ago)-57.1%
Dividend yieldNo dividend
Analyst consensusStrong Buy (20)
Average analyst price target$109.20 (+78%)

What they do

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

Momentum
35th percentile in sector
C-
12-1 return: +3.6%
Percentile within its GICS sector across the S&P 1500.
Growth
1st percentile in sector
F
Revenue growth (YoY): -57.1%
Percentile within its GICS sector across the S&P 1500.
Value
Not enough data yet
–
Forward E/P: – · EBITDA/EV: –
Percentile within its GICS sector across the S&P 1500.
Profitability
23rd percentile in sector
D
Profit margin: +0.0% · Return on equity: –
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

CYTK earningsNext report in 7 days
Next report · quarter Sep 2026
Wed Nov 4, 2026After the close
EPS consensus-$1.41 range -$1.65–-$1.10
Revenue consensus$41.6M 20 analysts
Last 4 quarters · EPS vs estimate
Aug 6, 2026-$1.50est -$1.60+6.3%Above estimates
May 5, 2026-$1.67est -$1.65−1.3%Below estimates
Feb 24, 2026-$1.50est -$1.37−9.7%Below estimates
Nov 5, 2025-$1.54est -$1.57+1.6%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-24 22:48:23 ET
24-1125-0225-0525-0825-1126-0226-0526-08-1.670.00
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$28.6M-57.1%
2026-03-31$19.4M–
2025-12-31$17.8M–
2025-09-30$1.9M–
2025-06-30$66.8M–

News & catalysts

More news
Cytokinetics to Announce Third Quarter Results on November 4, 2026
GlobeNewswire · Oct 21
William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates Coverage
Business Wire · Oct 21
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Oct 19
BridgeBio, Madrigal, Cytokinetics Trade Lower Ahead of Q3 Results Amid Lack of Near-Term Catalysts, BofA Says
MT Newswires · Oct 19
Can Myqorzo's Expansion and Growing Adoption Drive CYTK's Growth?
Zacks · Oct 19
Rating changes
Reiterated
2026-10-19 · HC Wainwright & Co. reiterated Buy on CYTK
Initiated
2026-10-16 · William Blair started covering CYTK at Outperform
Reiterated
2026-10-08 · RBC Capital reiterated Outperform on CYTK
Reiterated
2026-08-31 · HC Wainwright & Co. reiterated Buy on CYTK
Reiterated
2026-08-13 · Barclays reiterated Overweight on CYTK
Reiterated
2026-08-13 · JP Morgan reiterated Overweight on CYTK

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Malik Fady Ibraham
EVP Research & Development · 2026-10-20
Sell
$224.0K
Blum Robert I
Director, President & CEO · 2026-10-12
Sell
$471.6K
Malik Fady Ibraham
EVP Research & Development · 2026-10-06
Sell
$214.8K
Blum Robert I
Director, President & CEO · 2026-09-28
Sell
$490.9K
Malik Fady Ibraham
EVP Research & Development · 2026-09-22
Sell
$239.0K
Blum Robert I
Director, President & CEO · 2026-09-15
Sell
$6.8M
Landry Robert E
Director · 2026-09-15
Sell
$72.1K
Blum Robert I
Director, President & CEO · 2026-09-14
Sell
$550.8K
Landry Robert E
Director · 2026-09-11
Sell
$74.7K
Malik Fady Ibraham
EVP Research & Development · 2026-09-08
Sell
$264.1K
Parshall B Lynne
Director · 2026-09-01
Sell
$357.4K
Blum Robert I
Director, President & CEO · 2026-08-31
Sell
$526.8K

Stats refreshed 2026-10-24 22:48:23 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026